With fraud cases increasing, it is important to be alert and aware. By staying vigilant you can help protect yourself from being the victim of fraud.

Opportunities this week:

  • We are reiterating our BUY rating on GSK following a reassuring Zantac related news update. (BUY PT: £18.90)
  • We are reiterating our BUY rating on CRH after its solid Q2 2024 results release. (BUY PT: $93.10)
  • We are reiterating our BUY rating on FBD following a positive meeting with management last week. (BUY PT: €16.00)